142910-86-9

Basic information

• Product Name: N,N-Dimethyl-1H-indazole-3-methanamine
• Synonyms: N,N-Dimethyl-1H-indazole-3-methanamine;(1H-Indazol-3-yl)-N,N-diMethylMethanaMine;1-(1H-indazol-3-yl)-N,N-dimethylmethanamine
• CAS NO: 142910-86-9
• Molecular Formula: C₁₀H₁₃N₃
• Molecular Weight: 175.23032
• Mol File: 142910-86-9.mol

Chemical Properties

• Melting Point: 125-126℃
• Boiling Point: 302℃
• Flash Point: 137℃
• Appearance: /
• Density: 1.155
• PKA: 14.00±0.40(Predicted)
• CAS DataBase Reference: N,N-Dimethyl-1H-indazole-3-methanamine(CAS DataBase Reference)
• NIST Chemistry Reference: N,N-Dimethyl-1H-indazole-3-methanamine(142910-86-9)
• EPA Substance Registry System: N,N-Dimethyl-1H-indazole-3-methanamine(142910-86-9)

Safety Data

• Hazardous Substances Data: 142910-86-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
N,N-Dimethyl-1H-indazole-3-methanamine is used as a research compound for its potential biological activity, contributing to the development of new drugs in the pharmaceutical industry.
Used in Organic Synthesis:
In the field of organic chemistry, N,N-Dimethyl-1H-indazole-3-methanamine is used as a building block, facilitating the synthesis of complex organic molecules and compounds.

Upstream product

• 99055-81-9 1⁽²⁾H-indazole-3-carboxylic acid dimethylamide 
• 124-40-3 dimethyl amine 
• 5235-10-9 1H-indazole-3-carboxaldehyde 
• 43120-28-1 methyl 1H-indazole-3-carboxylate 

Downstream Products

• 1065220-21-4 endo-8-(1H-indazol-3-ylmethyl)-3-(4-chlorophenyl)-8-azabicyclo[3.2.1]octan-3-ol 

Relevant articles and documents

Synthesis and in Vitro Evaluation of Novel 5-Nitroindole Derivatives as c-Myc G-Quadruplex Binders with Anticancer Activity

Lead-optimization strategies for compounds targeting c-Myc G-quadruplex (G4) DNA are being pursued to develop anticancer drugs. Here, we investigate the structure-activity- relationship (SAR) of a newly synthesized series of molecules based on the pyrrolidine-substituted 5-nitro indole scaffold to target G4 DNA. Our synthesized series allows modulation of flexible elements with a structurally preserved scaffold. Biological and biophysical analyses illustrate that substituted 5-nitroindole scaffolds bind to the c-Myc promoter G-quadruplex. These compounds downregulate c-Myc expression and induce cell-cycle arrest in the sub-G1/G1 phase in cancer cells. They further increase the concentration of intracellular reactive oxygen species. NMR spectra show that three of the newly synthesized compounds interact with the terminal G-quartets (5′- and 3′-ends) in a 2 : 1 stoichiometry.

INDAZOLE DERIVATIVES

The present invention provides a compound represented by Formula (I): [whetein R1 represents CONR1aR1b (wherein R1a and R1b may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, substituted or unsubstituted ararkyl or a substituted or unsubstituted heterocyclic group, or R1a and R1b are combined together with the adjacent nitrogen atom thereto to form a substituted or unsubstituted heterocyclic group) or the like, R2 represents a hydrogen atom, CONR2aR2b (wherein R2a and R2b may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, substituted or unsubstituted ararkyl or a substituted or unsubstituted heterocyclic group, or R2a and R2b are combined together with the adjacent nitrogen atom thereto to form a substituted or unsubstituted heterocyclic group), NR2cR2d (wherein R2c and R2d may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkanoyl, substituted or unsubstituted aroyl, substituted or unsubstituted heteroaroyl, substituted or unsubstituted ararkyl, substituted or unsubstituted lower alkylsulfonyl or substituted or unsubstituted lower arylsulfonyl) or the like].

PROTEIN KINASE INHIBITOR

The present invention provides a protein kinase inhibitor (excluding c-Jun N-terminal kinase inhibitor) which comprises, as an active ingredient, an indazole derivative represented by Formula (I) (wherein R1 represents substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group) or a pharmaceutically acceptable salt thereof.